Figure 1: ATR inhibition is a compelling therapeutic target and overcomes TAZ resistance in rhabdoid tumors:

(A-B) metaVIPER analysis of rhabdoid tumor transcriptomes for proteins within OncoTarget (A) and the complete metaVIPER protein set (B). (C) Inhibitors rank-ordered by IC50 from Kuster et al. (D) DESeq2-normalized read counts of cells treated with 10 μM TAZ versus equivalent volume of DMSO for 11 days. n=3 biological replicates per condition. *p = 1.6E-6, **p = 1.3E-6, ***p = 1.2E-7 by two-sided Student’s t-test. (E) G401 cells treated with elimusertib for 4 days.